Sadasiva Katta, MD
Cardiovascular Disease · Huntsville, ALNPI 1952381444
Payments from drug & device makers
Across 666 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Amgen$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$979
- AstraZeneca$971
- Amarin Pharma, Inc.$831
- Johnson & Johnson$519
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,94897%
- Education$2823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 176 | $1,681 |
| Amgen | 95 | $1,440 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 71 | $979 |
| AstraZeneca | 58 | $971 |
| Amarin Pharma, Inc. | 50 | $831 |
| Johnson & Johnson | 41 | $519 |
| Boehringer Ingelheim | 20 | $476 |
| Bayer | 20 | $424 |
| Esperion Therapeutics, Inc. | 19 | $328 |
| Novo Nordisk | 12 | $273 |
| E.r. Squibb & Sons, L.L.C. | 15 | $271 |
| Astellas Pharma US Inc | 5 | $220 |
| Boston Scientific | 8 | $192 |
| Philips North America LLC | 9 | $176 |
| Merck | 7 | $169 |
| Sanofi-aventis U.S. LLC | 10 | $158 |
| Impulse Dynamics (USA) Inc. | 2 | $134 |
| Abiomed | 2 | $134 |
| Arbor Pharmaceuticals, Inc. | 6 | $90 |
| Pfizer | 5 | $88 |
| Cardiovascular Systems Inc. | 2 | $84 |
| Scpharmaceuticals Inc. | 5 | $77 |
| Braemar Manufacturing, LLC | 1 | $67 |
| Lexicon Pharmaceuticals, Inc. | 4 | $64 |
| Abbott | 3 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| CSL Behring | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Cardiva Medical, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| GSK | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $14 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,230 in reported general payments places this provider in the 75th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 782 | $912,514 |
| EntrestoSacubitril/Valsartan | 576 | $664,606 |
| JardianceEmpagliflozin | 361 | $391,435 |
| XareltoRivaroxaban | 261 | $263,315 |
| FarxigaDapagliflozin Propanediol | 238 | $261,076 |
| Repatha SureclickEvolocumab | 229 | $213,628 |
| BrilintaTicagrelor | 92 | $67,952 |
| Repatha SyringeEvolocumab | 37 | $41,187 |
| VascepaIcosapent Ethyl | 43 | $33,132 |
| Metoprolol Succinate | 1,333 | $23,757 |
| Rosuvastatin Calcium | 1,040 | $19,351 |
| Ezetimibe | 535 | $14,955 |
| Atorvastatin Calcium | 1,051 | $14,874 |
| Icosapent Ethyl | 36 | $14,614 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 102 | $13,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $912,514782 claims |
| NovartisEntresto | $1,681 | $664,606576 claims |
| Boehringer IngelheimJardiance | $476 | $391,435361 claims |
| AstraZenecaFarxiga, Brilinta | $971 | $329,028330 claims |
| Johnson & JohnsonXarelto | $519 | $263,315261 claims |
| Esperion Therapeutics, Inc.Nexletol | $328 | $9,97716 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $58 | $7,96518 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $90 | $7,16818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Huntsville
- Walter HaughtHuntsville$1.6M
- Shi-Chi ChengHuntsville$1.2M
- Vernon HunterHuntsville$778K
- Phillip LaneyHuntsville$283K
- Michael RidnerHuntsville$216K
- Enrique VelasquezHuntsville$124K
- James MurphyHuntsville$115K
- Rashida AbbasHuntsville$45K
- Warren StricklandHuntsville$14K
- Mustafa AhmedBirmingham$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.